full screen background image
Friday 23 February 2024
  • :
  • :

CURA Healthcare Launches Illumina 3600 – World’s First-Ever Robotic, 360 degree Breast Thermography System.







CURA Healthcare Launches Illumina 3600 – World’s First-Ever
Robotic, 360 degree Breast Thermography System.

 CURA removes barriers to early detection & early age breast screening with illumina 3600
 No Pain, No Radiation, No Touch, No Breast Exposure, Non-invasive solution for all women above 18 years.
 Earlier detection of breast anomalies – years ahead of current methods
 Designed, Developed and Made in India with support from Govt. of India

Photo Caption: IMG 01891- Mr N Kannan, Director New Product Development, Dr Sandeep Jaipurkar, Radiologist at Vijaya Health Centre and Breast Clinic, Chennai, M Bala, President and CEO of CURA Healthcare.





CURA Healthcare Launches Illumina 3600 – World’s First-Ever Robotic, 360 degree Breast Thermography System.

• CURA removes barriers to early detection & early age breast screening with illumina 3600.
• No Pain, No Radiation, No Touch, No Breast Exposure, Non-invasive solution for all women above 18 years.
• Earlier detection of breast anomalies – years ahead of current methods
• Designed, Developed and Made in India with support from Govt. of India

Chennai – October 31, 2017 – CURA Healthcare announced today the launch of world’s first, robot-assisted digital 360 degree breast thermography device, an early breast cancer warning system for all age groups. CURA’s illumina 3600 can detect breast anomalies several years ahead of prevalent breast cancer screening methods without causing pain due to compression, without non-ionizing radiation and without human touch. illumina 3600 is designed, developed and manufactured in India with the support of BIRAC, Department of Biotechnology, Government of India.

“With illumina 3600, we believe we have removed most of the barriers to early breast screening – Pain, discomfort, radiation safety, and breast exposure. illumina 3600 detects disease years earlier than today’s conventional screening modalities and when it is addressable without invasive and painful procedures. We believe, our illumina can be a big game changer in breast healthcare and with it mass breast screening from early ages can be a reality now in India”,” said M Bala, President and CEO of CURA Healthcare. “illumina 3600 is co-created by women, leading healthcare providers and our experienced engineers to disrupt and transform the way breast screening and monitoring is done today. It represents CURA’s commitment to a ”Aarogya Bharath” through friendly, affordable and accessible technology solutions.” He added.

“We at BIRAC are here to stimulate, foster and enhance bio-tech innovation that can bridge existing healthcare gaps and improve lives of 1.3 billion Indians. This is a critical mandate of Government of India. We are pleased to announce the birth of one such innovation – CURA’s illumina 3600, to bridge one of the biggest gaps in the country – addressing the biggest killer disease of the country – Breast Cancer. We are proud to have been part of innovating this disruptive innovation” said Dr Renu Swaroop, Managing Director, Bio-technology Industry Research Assistance Council (BIRAC), Department of Bio-Technology, Government of India.

Today, India is staring at a breast cancer epidemic and breast screening is non-existent in India. 1 in 28 women get breast cancer and 1 in 2 die due to late detection, making survival one of the lowest in the world. Early detection programs in developed countries have shown that early screening can help reverse the trend. In USA, 90% of the breast cancer patients lead a long, healthy life due to early detection and early intervention. Studies report that only about 12% of women diagnose breast cancer and over 70% presenting in late stages when it is fatal and treatment is not efficient, while lack of awareness is a major reason, those who are aware also opt out of screening due to pain and discomfort. In India, breast cancer is increasingly prevalent among the young and by over a decade. Mammography is prescribed for above 45 years age groups only and hence is not available to a large 285 million population of younger women.

illumina 3600 helps in identifying breast anomalies years ahead of current screening methods: The breast is a highly complex and one of the most difficult to image human organ as it varies in symmetry, density, size and morphology. Breast tissue is unique due to the mechanism of the mammary vessels, fatty tissue and skin temperatures. Substantial changes could occur to this organ during hormonal changes and different stages of life. Measurement and studying of breast skin (skin is the largest organ of the body with maximum blood circulation- about 25%) temperature and its response to hot and cold challenges in a controlled environment plays an important role in early detection of breast anomalies. illumina 3600 can provide truly early insight into breast care through identification of early breast tissue changes. illumina images allow doctors to differentiate between normal and abnormal breast tissues that may develop or be caused by cysts, estrogen dominance, or fibrous tissue and potentially cancerous tissues. Most cancerous tissues require greater degree of metabolic activity and vascular/blood circulation and hence will emit an increased regional temperature. The advanced ultra-sensitive infrared camera of illumina 3600 aided by an advanced robot can sense these variations through varying temperature patterns and help detect tissue changes over time. The extreme sensitivity and 360 degree coverage together with advanced digital processing can help detect the earliest thermal signs suggesting pre-cancerous stage of breast tissues or the presence of a tumor that is not yet large enough to be detected by physical examinations, and structural imaging tools. illumina 3600 provides early warning signs on breast cancer just how satellite images provide early warning signs of storms and hurricanes.

A traditional mammography system can detect breast cancer only when it reaches a cluster of 4 billion cells or the size of a grape or 1 CM size. illumina 3600 produces these early warning signs at over 97% accuracy without compressing the breast, radiation and any discomfort to the patient making it very attractive for women of all age groups. illumina 3600 can be used for unlimited, repeated exams as it does not emit radiation and is safe. Breast thermography is approved by FDA as an adjunct screening method to current standard of mammography.

“illumina 3600 ushers in a new age in breast care. illumina 3600 is like a thermometer for the breast health assessment. An exam conducted as comfortable as an early thermometer test during fever. The high sensitivity camera of illumina 3600 can detect the minutest heat changes in the breast to indicate the presence of anomalies at cellular levels. A mammography or ultrasound imaging can re-confirm its findings and together, it can be a life saver for all our women as the detection takes place years in advance and preventive measures can be taken.” Said Dr Sandeep Jaipurkar, Radiologist at Vijaya Health Centre and Breast Clinic, Chennai.” Dr Sandeep Jaipurkar was one of the key partners in development of CURA’s illumina 3600 and principal clinical partner for over 5 years with 5000 case studies.

“Many of my patients tell me that mammography is painful experience. illumina 3600 can attract all those women who found the pain, radiation risk, touch and breast exposure a major deterrent in opting for the screening exam.” Said Prof. Kalpana, Radiologist, Madras Medical College and Rajiv Gandhi General Hospital who acted as a key partner in clinical investigations using CURA’s illumina 3600.

“No woman should miss out on the potentially life-saving benefits of regular breast screening out of pain, fear, anxiety or discomfort. Illumina 3600 designed with empathy after years of observation and studies of how breast screening is done today. It humanizes the mammography experience by increasing comfort and reducing patient anxiety just as in a spa. With illumina’s capability to provide 360 view of early breast tissue changes and intelligent analysis, we believe breast cancer cannot hide any more. The system’s potential to help increase the number of annual screening exams is a critical advancement in women’s healthcare.” said N Kannan, Head, New Product Development at CURA Healthcare.

illumina 3600 IS HIGHLY BENEFICIAL IN RADIATION FREE TREATMENT MONITORING: illumina 3600 with its radiation free imaging can be used for unlimited repeat exams to monitor the effectiveness of treatment procedures. Its findings at the early stages can change the approach to treatment or alter the course or confirm how well the treatment is working. With illumina 3600 now doctors can protect patients from high radiation as well as high costs per exam. Today, patients are subjected to a PET/CT exam, for monitoring of treatment, which emit radiation levels of 25 mSv equivalent to 8 years of natural background radiation.

About CURA Healthcare:
CURA means Care. True to our name, we are dedicated to provide transformational healthcare solutions that can shape a new age of patient care through early detection and early treatment. Since our birth in 2001, we have been innovating and making advanced healthcare solutions in India that can help improve the curability of diseases. We have been enhancing the reach of these solutions in the remotest parts of India to improve quality and affordability of care.
Media Contact:
Manoj V Menon, Commistry.- +91 9845199852. manoj@commistry.com
Ve Ve Prabhu, Accolade PR. +91 99406 36961 accolade.publicrelations@gmail.com
1. CURA Breast Cancer Fact Sheet
2. Product Photographs, Videos
Also available at: www.illumina360.in



October 31, 2017

 Breast cancer is the most common cancer in women in India and accounts for 27% of all cancers.
 1 in 28 women in India likely to develop breast cancer during her life time. India has a breast cancer incidence rate of 25.8/100,000 compared to 124.9/100000 of USA. However India has one of the lowest survival rates. 144,937 cases were diagnosed in India in 2012 with a prevalence of 396,990 patients. 70,218 of them did not survive the first 5 years.

 The average age for breast cancer in India is almost a decade lower than that in the west. Cancer in the young is extremely aggressive. Incidence rates begin to rise in the early thirties and peak at ages 50-64 years. 15-34 = 4.24%; 34-50 at 16%; Disease peaks in 40-50 among Indian women.

Shifting to Young – Breast cancer incidence & mortality is increasing among the young aged 30-50 years.

EARLY DETECTION: at younger age improves survival and healthy life.(<35 years)  India does not have a breast cancer screening policy. Breast cancer screening/diagnosis infrastructure and access is very limited.  Mammography, FDA approved screening method is recommended for women aged 45 and above. Mammography misses out about 13% of cancers depending on age and density of breast. Overall screening mammogram misses out 1 in 5 breast cancers. (ACC). Mammography shows more false negatives in dense breasts.  Only 12.5% women go for any kind of screening/diagnosis. Over 50% of breast cancer patients reported in advanced stages in India where as it is just 12% in the West. Socio-cultural issues are a big barrier in voluntary screening. (IJRMS)  70-80% in rural areas does not approach hospitals even during end stage.  As per Registrar General of India have about 612 Million women in the age group of 15-80 out of which appx. 280 Million are in the 18-40 years age group who does not come under the FDA screening age recommendation.  Younger Indians tend to have more dense breasts, where detection of disease is even more difficult with current imaging methods available in India. Over 95% of mammography systems in use in India are conventional mammography while digital mammography systems are considered more effective for dense breasts. SCREENING TECHNOLOGIES & EFFECTIVENESS: Breast cancer develops from cells in the breast. The most common sign of breast cancer is a new lump or mass, but most are benign. The other signs include a generalized swelling of part of a breast (even if no lump is felt), skin irritation or dimpling, nipple pain or retraction, redness or scaliness of the nipple or breast skin, or a spontaneous discharge other than breast milk. The earlier breast cancer is found, the better the chances for successful treatment or preventive measures. A mammogram can often show breast changes that may be cancer before symptoms develop. A Thermogram is an FDA approved adjunct device and is capable of spotting breast anomalies at the earliest i.e. changes in the first few cells. CURA Illumina 3600 world’s first dedicated 3600 view breast thermography system. The low survival rates in India and less developed countries can be explained mainly by the lack of early detection programs, resulting in a high proportion of women presenting with late-stage disease, as well as by the lack of adequate diagnosis and treatment facilities. RADIATION. TREATMENT / THERAPY MONITORING & SURVEILLANCE  One PET/CT causes 25 mSv of radiation levels, equivalent to 8 years of natural background radiation.  A CT scan causes 10mSv of radiation levels. i.e. 3 years of natural background radiation  A Mammogram causes 0.4 mSv. i.e. 7 weeks of natural background radiation  A chest x-ray causes 0.1 mSv. – 10 days of natural background radiation. BOTTOM LINE: Early detection can help save lives and treatment or preventive measurements are most successful. ADDITIONAL INFORMATION: RISKS & CAUSES:  A woman’s risk of breast cancer nearly doubles if she has a first-degree relative (mother, sister, and daughter) who has been diagnosed with breast cancer.  Less than 15% of women who get breast cancer have a family member who has been diagnosed with it.  About 5-10% of breast cancers are thought to be caused by inherited gene mutations (abnormal changes passed through families).  Mutations of the BRCA1 and BRCA2 genes are the most common. Women with a BRCA1 mutation have, on average, a 55-65% risk of developing breast cancer in their lifetimes. For women with a BRCA2 mutation, the lifetime risk is 45%. An increased ovarian cancer risk is also associated with these genetic mutations.  The most significant risk factors for breast cancer are gender (being a woman) and age (growing older) REFERENCES: WHO http://www.who.int/cancer/detection/breastcancer/en/index1.html Globocan, ICMR, Cancer Today http://onlinelibrary.wiley.com/doi/10.1111/ajco.12661/abstract Cancer India http://cancerindia.org.in/index.php/know-about-cancer/statistics#breast-cancer ; http://www.cancerindia.org.in/index.php/know-about-cancer/cancer-factsheet SEER https://seer.cancer.gov/statfacts/html/breast.html Nice graphs…recreate International Journal of Community Medicine & Public Health http://www.ijcmph.com/index.php/ijcmph/article/view/864/746 Breast Cancer India : http://www.breastcancerindia.net/statistics/trends.html American Cancer Society, Breast Cancer Facts. National Cancer Registry Program, India IJRMS http://www.msjonline.org/index.php/ijrms/article/view/1084/1044 Cancer Research, UK : http://www.cancerresearchuk.org/about-cancer/what-is-cancer/how-cancers-grow https://www.radiologyinfo.org/en/pdf/safety-xray.pdf http://www.wcrf.org/int/research-we-fund/continuous-update-project-findings-reports/breast-cancer IMG_0179

Leave a Reply

Your email address will not be published. Required fields are marked *